Table 2 Characteristics of patients with AIFRS (n = 70)
| Â | No. (%) |
|---|---|
Age (mean ± SD, range) | 52.5 ± 14.2, 24–89 years |
Gender | |
 Male | 36 (51.4) |
 Female | 34 (48.6) |
Comorbidities/Risk factors | |
 Ongoing DM | 33 (47.1) |
 Denovo DM | 26 (37.1) |
 CKD | 4 (5.7) |
 AML | 3 (4.3) |
 Kidney transplantation | 1 (1.4) |
 COVID-19 + Systemic steroid | 3 (4.3) |
Presenting symptoms | |
 Facial pain and swelling | 49 (70) |
 Headache | 31 (44.3) |
 Facial numbness | 41 (58.6) |
 Nasal congestion | 46 (65.7) |
 Visual deterioration | 21 (30) |
 Eyelid drooping | 22 (31.4) |
 Restricted eye movements | 12 (17.1) |
Stage | |
 Stage 1 | 7 (10) |
 Stage 2 | 29 (41.4) |
 Stage 3 | 25 (35.7) |
 Stage 4 | 9 (12.9) |
Orbital involvement | |
 Orbit involving disease | 34 (48.6) |
 Orbit sparing disease | 36 (51.4) |
Affected side | |
 Right | 40 (57.1) |
 Left | 28 (40) |
 both | 2 (2.9) |
Organism | |
 Mucor | 50 (71.4) |
 Aspergillus | 4 (5.7) |
 Both | 3 (4.3) |
 No data | 13 (18.6) |
Outcome | |
 Died | 25 (35.7) |
 Survived | 45 (64.3) |